Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Network Pharmacology and Molecular Docking Reveal Neuroprotective Potential of <i>Ligusticum wallichii</i> in Alzheimer's Disease Therapy

Zhou C., Peng Y.

Laboratory Study on Neuroinflammation, Chronic Inflammation, published in Neuropsychiatr Dis Treat (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Neuropsychiatr Dis Treat (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41341539
PMCID
PMC12669057
DOI
10.2147/ndt.s523834

Abstract (original English)

Purpose In traditional Chinese medicine, Ligusticum wallichii is a prominent herb, acclaimed for its therapeutic roles, including anti-tumor, antioxidant, and anti-inflammatory benefits. Studies conducted recently suggest it may help reduce cognitive deficits linked to Alzheimer's disease. However, the precise neuroprotective pathways through which Ligusticum wallichii exerts its effects on Alzheimer's disease are not yet fully understood. Network pharmacology is utilized in this research to understand the mechanisms through which Ligusticum wallichii 's active ingredient might protect against Alzheimer's disease. Methods The TCMSP database was utilized to extract the bioactive compounds of Ligusticum wallichii , and their related molecular targets were identified. By querying the GeneCards and OMIM databases, targets associated with Alzheimer's disease were identified. Using Cytoscape 3.8.2, a regulatory network mapping the interactions between active compounds and their respective targets was constructed. A protein-protein interaction network was generated by analyzing the target genes influenced by Ligusticum wallichii in Alzheimer's disease using the String database. The DAVID database was utilized to perform functional enrichment analysis, encompassing Gene Ontology (GO) and KEGG pathway analyses, to identify possible biological pathways related to these targets. Following

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research